Conseil d'examen du prix des médicaments brevetés

IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4, as amended

AND IN THE MATTER OF Alexion Pharmaceuticals Inc. (the "Respondent") and the medicine "Soliris"

ORDER REGARDING SCHEDULING

Decided by the Hearing Panel on the basis of the written record Date of Order: March 13, 2015

- 1. FURTHER to the notice of hearing issued by the Patented Medicine Prices Review Board (the "Board") Secretariat on January 20, 2015 in the above matter;
- 2. AND FURTHER to the Board order regarding scheduling of February 13, 2015;
- 3. AND FURTHER to the response filed by the Respondent on March 9, 2015;
- 4. AND FURTHER to a request filed by counsel for Board Staff on March 11, 2015 seeking an order extending the time to file a Reply in accordance with section 19 of the Patented Medicine Prices Review Board Rules of Practice and Procedure (the "Rules").

THE BOARD ORDERS THAT:

An extension of time for Board Staff to file a Reply in conformity with section 19 of the Rules is granted until April 10, 2015.

DATED at Ottawa, this 13th day of March, 2015

Dr. Mitchell Levine

mitchell Levino





COUNSEL / REPRESENTATIVES:

For Board Staff:

Parul Shah David Migicovsky Chris Morris

For the respondent:

Alan West Malcom Ruby

For British Columbia:

Barbara Walman